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Abstract Introduction Professor Archibald Cochrane,
after whom the Cochrane Collaboration is named, was
influential in promoting evidence-based clinical practice.
He called for ‘‘relevant, valid research’’ to underpin all
aspects of healthcare. Systematic reviews of the literature
are regarded as a high quality source of cumulative evi-
dence but it is unclear how truly systematic they, or other
review articles, are or ‘how systematic is systematic?’
Today’s evidence-based review industry is a burgeoning
mix of specialist terminology, collaborations and founda-
tions, databases, portals, handbooks, tools, criteria and
training courses. Aim of the review This study aims to
identify uses and types of reviews, key issues in planning,
conducting, reporting and critiquing reviews, and factors
which limit claims to be systematic. Method A rapid
review of review articles published in IJCP. Results This
rapid review identified 17 review articles published in IJCP
between 2010 and 2015 inclusive. It explored the use of
different types of review article, the variation and widely
available range of guidelines, checklists and criteria which,
through systematic application, aim to promote best prac-
tice. It also identified common pitfalls in endeavouring to
conduct reviews of the literature systematically. Discussion
Although a limited set of IJCP reviews were identified,
there is clear evidence of the variation in adoption and
application of systematic methods. The burgeoning evi-
dence industry offers the tools and guidelines required to
conduct systematic reviews, and other types of review,
systematically. This rapid review was limited to the
database of one journal over a period of 6 years. Although
this review was conducted systematically, it is not pre-
sented as a systematic review. Conclusion As a research
community we have yet to fully engage with readily
available guidelines and tools which would help to avoid
the common pitfalls. Therefore the question remains, of not
just IJCP but potentially all published reviews, ‘how sys-
tematic is systematic?’
Keywords Critical appraisal  Data extraction 
Literature  Review  Systematic review
Impacts on practice
• Today’s evidence-based review industry is a burgeon-
ing mix of specialist terminology, collaborations and
foundations, databases, portals, handbooks, tools, cri-
teria and training courses.
• Minimising bias is often aided by the independent
application of recognised, standardised tools by more
than one researcher conducting a review.
• As a research community we have yet to fully engage
with readily available guidelines and tools which would
help to avoid the common pitfalls in conducting
reviews systematically.
Introduction
Professor Archibald Cochrane, after whom the Cochrane
Collaboration is named, was influential in promoting evi-
dence-based clinical practice when he called for,
‘‘the conscientious use of current best evidence in
making decisions about the care of individual patients
& Katie MacLure
k.m.maclure@rgu.ac.uk
1 School of Pharmacy and Life Sciences, Robert Gordon
University, Aberdeen AB10 7GJ, Scotland, UK
123
Int J Clin Pharm (2016) 38:685–694
DOI 10.1007/s11096-016-0288-3
or the delivery of health services. Current best evi-
dence is up-to-date information from relevant, valid
research about the effects of different forms of health
care’’ [1].
Today’s evidence-based review industry is a burgeoning
mix of specialist terminology, collaborations and founda-
tions, databases, portals, handbooks, tools, criteria and
online training courses. Although systematic reviews and
meta-analyses of randomised controlled trials (RCTs) are
considered the gold standard within the hierarchy of evi-
dence ahead, in order, of RCTs, cohort studies, case con-
trol, case series and case reports, qualitative studies,
editorial articles and commentaries, pharmacists and
researchers will benefit from an informed and critical
approach to questioning the validity and applicability of
published findings. Sir Ian Chalmers, celebrated health
services researcher and one of the founders of the Cochrane
Collaboration, favoured systematic reviews,
‘‘because the results of a particular research study
cannot be interpreted with any confidence unless they
have been synthesised, systematically, with the
results of all other relevant studies. Science is meant
to be cumulative, but researchers usually don’t
cumulate scientifically’’ [1].
Readers need to understand the differences between the
many types of review as only well-conducted systematic
reviews provide the highest level of evidence.
Grant and Booth’s [2] typology of 14 different types of
review does not include either narrative reviews or reviews
of reviews (critical, literature, mapping, meta-analysis,
mixed methods, overview, qualitative systematic, rapid,
scoping, state-of-the-art, systematic, systematic search and
review, systematized, umbrella). It does, however, describe
literature reviews as generic, which may or may not
include systematic, comprehensive searching and quality
assessment with narrative synthesis of findings often
reported chronologically or thematically [2]. In contrast,
systematic reviews are described as comprehensive and
exhaustive, which ‘‘systematically search for, appraise and
synthesise research evidence, often adhering to guidelines
on the conduct’’ before reporting on, ‘‘what is known,
recommendations for practice, what remains unknown,
uncertainty around findings, recommendations for future
research’’ [2]. So, while all literature reviews may be
undertaken systematically, systematic reviews aim to
appraise and synthesise evidence to answer specific review
question(s) following a protocol written in advance. It is
not unusual for reviews to be described by authors as
systematic reviews when in actual fact they are narrative
overviews of the available literature within a given field but
do not aim to answer a specific review question. Therefore,
it is especially important to understand and be able to
critically appraise any review of the literature by posing the
question, ‘how systematic is systematic?’ [1–6]?
Aim of the review
This study aims to identify uses and types of reviews, key
issues in planning, conducting, reporting and critiquing
reviews, and factors which limit claims to be systematic in
practice.
Method
A rapid review of the IJCP publications database
(2010–2015) was conducted to identify articles with ‘re-
view’ in the title. Data were extracted to demonstrate the
range of review types presenting as systematic in title,
systematic in method or—through the application of a
range of guidelines, criteria and tools—systematic in con-
duct to provide evidence in answering the challenge ‘how
systematic is systematic?’.
Results
Seventeen articles were identified from their title as being
forms of review of which ten were systematic reviews,
three were reviews of reviews, two were narrative reviews
and two were literature reviews (Table 1) [7–23].
Uses: the types and purposes of reviews
As shown by the 17 identified IJCP review articles
(Table 1), reviews cover the spectrum of healthcare
including drugs, technologies, pharmacy practice and
practice of the wider, often multidisciplinary, health and
social care team. The articles for inclusion in a systematic
review may be reporting primary data based on qualitative
(often interviews or focus groups), quantitative (surveys or
RCTs), mixed methods or based on secondary data repor-
ted cumulatively in systematic reviews (a review of
reviews). The systematic review is typically written in a
narrative (descriptive) form with accompanying tables de-
scribing the included, cumulative evidence but other vari-
ations include critical, rapid, literature, meta-narrative
scoping and reviews of systematic reviews [2]. The Centre
for Review and Dissemination at the University of York
recommends checking for existing systematic reviews
already registered or conducted (DARE, CDSR, NICE,
686 Int J Clin Pharm (2016) 38:685–694
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NIHR HTA, EPPI, NGC, SIGN)1 while also scoping the
breadth of the relevant literature (MEDLINE, EMBASE,
CINAHL, IPA, ERIC) [24]. If an existing systematic review
is found, is it clearly relevant, valid and of good quality; is
there a clear need for it to be updated or extended?
Pharmacists can benefit from gaining experience of
considering where application of high quality relevant
findings can bridge the evidence gaps and so promote
safety, efficacy and effectiveness of evidence-based phar-
maceutical interventions.
The reasons for conducting a systematic review are
many and varied including to:
• identify, evaluate and interpret available research
evidence relevant to a particular topic;
• identify effective and ineffective healthcare
interventions;
• help inform practice and policy by providing integrated
and unbiased evidence on which to base decisions; and
• identify gaps in the literature to inform future studies [1].
As systematic reviews, ‘‘aim to minimize bias by using
explicit, systematic methods’’, a review protocol is devel-
oped, and often registered or published, which sets out the
methods to be used,
‘‘including decisions about the review question,
inclusion criteria, search strategy, study selection,
data extraction, quality assessment, data synthesis
and plans for dissemination’’ [24].
Elements of a systematic review protocol
A well formulated protocol is an essential component of a
systematic review as it guides the course of the whole review
process and differentiates from other types of reviews. Starting
from a specific and targeted review question, then outlining
resources for gathering all relevant studies, systematic review
protocols enable predetermined and explicit method of
undertaking a systematic review through to write up and dis-
semination. The systematic review protocol aims to describe
the plans to be followed in the review, designed to minimise
bias by explicitly stating a priori hypotheses and methods,
without advance knowledge of results [24–26]. Of the 17
review articles identified (Table 1), only three mention a
predetermined review protocol but none published a protocol.
Depending on the healthcare subject area, the protocol may
be accepted for registration with institutions such as one of
fifty-three Cochrane Review Groups or the Joanna Briggs
Institute (JBI)—both of whom require approval of a title
registration form prior to development of the review proto-
col—or PROSPERO which is associated with CRD [27–29].
But registration of a protocol necessitates a commitment to
maintaining an auditable log of any changes. Some, including
Cochrane, ask the authors to commit to regular updates which
the resourceful reviewer will facilitate by saving searches in
key databases and setting up email alerts from key sources.
Some journals, for example BioMed Central or the System-
atic Review Journal, also accept systematic review protocols
for publication [30, 31]. The recent publication of PRISMA-P
(2015) is a welcome additional guide to writing systematic
review protocols [32]. Moher et al. [32] suggest ‘‘peer
reviewers and editors can use the guidance to gauge the
completeness and transparency of a systematic review pro-
tocol submitted for publication’’. The PRISMA-P checklist
consisting of 17 items (Table 2) was developed through
consensus methods guided by an international steering group
of experts in systematic reviews drawing on best practice
from CDSR, PROSPERO, AHRQ and more [27, 29, 40].
A published protocol also alerts to the healthcare community
that a review is underway providing an audit trail for changes to
the protocol. Yet none of the reviewed IJCP articles (Table 1)
had published a peer reviewed systematic review protocol.
Clear review question
The systematic review question will determine the type of
studies to be included whether quantitative, qualitative,
mixed methods, a review of reviews or a combination.
The review question is often written in a formulaic
fashion. For example, ‘‘A systematic review of medical and
non-medical practitioners’ views of the impact of ehealth’’
or ‘‘Non-medical prescribing versus medical prescribing
for acute and chronic disease management in primary and
secondary care’’ [33, 34]. Each includes and demonstrates
the use of ‘‘PICOS’’ (P:population; I:intervention; C:com-
parator; O:outcome; S:setting or study design) [35].
Additions or alternatives include ‘‘T’’ for timeline or ‘‘P’’
as phenomenon of interest. All but one of the identified
reviews (Table 1) included a clear review question. The
exception varied the focus between evaluation, influence
and impact of pharmacist care; each a very different term
with clear implications for reporting review findings.
Independence within reviews
Included in the protocol should be statements about the role
of team members in undertaking independent review of the
titles, abstracts and full texts, also how any disagreements
1 DARE (Database of Abstracts of Reviews of Effects); CDSR
(Cochrane Database of Systematic Reviews); NICE (National Insti-
tute for Health and Clinical Excellence); NIHR HTA (National
Institute for Healthcare Research Health Technology Assessment);
EPPI (Evidence for Policy and Practice Information) Centre; NGC
(National Guidelines Clearinghouse; SIGN (Scottish Intercollegiate
Guidelines Network).
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will be resolved, perhaps by a third member of the team.
These steps help to minimise bias and promote trans-
parency of process but in many reviews independence of
activity is limited to applying quality criteria thus reducing
rigour in the search process, data extraction and reporting
aspects. The majority of the rapid review articles (Table 1)
make clear statements about author roles but one of the
reviews limited independent activity to quality assessment,
another review sought to justify lack of independent review
by following a narrative review process while a third, a
systematic review, did not define team roles.
Common pitfalls of published reviews: lack of a
detailed, published protocol to guide all steps of the
review; lack of team experience, expertise and independent
involvement throughout; lack of independent review or
plans for reaching consensus.
Guidelines and tools for locating, selecting
and critically appraising the literature
The search strategy should detail what to look for, how to
look for and where to look for (un)published and grey
literature (reports, theses, opinion pieces and conference
proceedings) plus inclusion/exclusion criteria relevant to
the review which will likely include:
Concept mapping
• an important tool in considering alternative search
terms, similar to a thesaurus but considering alternative
spellings and terms adopted in different countries of
practice. Building up search strings as well as under-
standing the relationships between terms can be eased
by working with an experienced team [36];
MeSH (Medical Subject Headings)
• are also helpful in identifying keywords to be combined
using Boolean AND/OR/NOT, truncation and wildcard
alternatives specific to each database or portal [37];
Language and date inclusions
• perhaps linked to the publication of a seminal text,
event or paper identified during the research process or
a previous relevant systematic review but must be fully
evidenced and justified;
Recording the activity
• of locating and selecting studies using, for example, a
PRISMA flowchart alongside spreadsheets to record
inclusions/exclusions with reasons for exclusion. The
selection process starts with at least two reviewers
independently screening titles for inclusion, then
abstracts followed by full texts of studies noting, ‘‘if
in doubt keep it in’’ [38];
Table 2 Extracts from the PRISMA-P 2015 checklist [32]
Section/topic # Item
Title 1 Identification
Update
Registration 2 Name of the registry
Authors 3 Contact
Contributions
Amendments 4 State plan for documenting
Support 5 Sources
Sponsor
Role of sponsor/funder
Introduction 6 Rationale
7 Objectives
Methods 8 Eligibility criteria
9 Information sources
10 Search strategy
11 Study records (data management; selection process; data collection process)
12 Data items
13 Outcomes and prioritization
14 Risk of bias in individual studies
15 Data synthesis
Meta-bias(es) 16 Specify plans
Confidence in cumulative evidence 17 How assessed
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Critical appraisal
• choosing and applying tools relevant to the type of
studies identified, considering the unit of analysis
(patient, control or study group), quality of the articles
and potential for data synthesis: do identified studies
use the same unit of analysis or the same elements of
PICOS/T?; do studies meet quality criteria or are there
so few studies that quality or study design is less
relevant? Commonly used tools include those provided
by the Cochrane Collaboration, Joanna Briggs Institute
(JBI), CASP (Critical Appraisal Skills Partnership) and
CEBM (Centre for Evidenced Based Medicine), all
offering checklists aligned to study design [1, 28, 35,
39];
Data extraction
• taking meaningful and relevant data from included
studies is important in the systematic review process.
Data extraction tools should be developed by the
review team and piloted against samples of included
literature;
• designing or adapting existing tools, plans for dealing
with missing data, or applying subgroup analyses using
dedicated software (for example, Cochrane’s RevMan;
JBI’s Sumari and Connect ?) available to authors,
consideration of assessment of risk of bias, assessment
of heterogeneity (difference in units of analysis which
may prevent synthesis), sensitivity or specificity anal-
yses (ability of the search to identify a breadth of
studies which are of direct relevance) and, where
appropriate, measures of treatment effect [1, 28]. Most
importantly, all the evidence indicates that data
extraction should be conducted by at least two
researchers operating independently or following the
option of blinding;
Reducing bias in cumulative evidence
• systematic reviews adopt a robust and rigorous
approach aimed at reducing bias and errors during the
identification, quality assessment and synthesis (possi-
bly statistical combination) of relevant studies [1]. Bias
is the ever present ‘devil in the detail’ with the potential
to undermine the quality of any review [25, 26]. It takes
many forms, for example selection, omission, commis-
sion, source, availability and reporting bias in sourcing,
including and excluding articles from a review;
• bias can affect the quality of primary data of an article
considered for inclusion in a review. Sampling errors,
construct validity of variables, bias in the effect size
undermine the intended objectivity. Systemic error
through bias introduced into any phase of research,
including study design, data collection, synthesis,
analysis and publication may skew reported outcomes
[25, 26];
• minimising bias is often aided by the application of
recognised, standardised tools but seven of the 17
review articles (Table 1), including three systematic
reviews, did not report the use of standardised tools.
Common pitfalls of published reviews: lack of focus in
the research question(s), bias, drifting from the primary
outcome, lack of team experience and subject/method-
ological expertise.
Discussion
Many of the evidence-based industry sites have links to
frequently asked questions (FAQs), online training and
encouragement to conduct systematic reviews including
templates, checklists and software for building reports.
Online and face-to-face training options are readily avail-
able and are strongly recommended for anyone considering
undertaking a systematic review. Despite the ready avail-
ability and broad range of tools, the 17 reviewed articles
(Table 1) demonstrate use of only a limited range of those
tools and only applied to limited parts of the review
process.
Common pitfalls of published reviews: time spent
developing original tools but conversely using tools not
adapted to purpose, lack of independent review within the
team which is especially an issue where systematic reviews
are undertaken as part of an academic activity (student-led
review may have limited supervisor input).
The ‘‘must do’’ list for systematic reviews
There are many guidelines and checklists available from
which to create a ‘‘must do’’ list for systematic reviews [1,
4, 24, 27–30, 32, 38–44]. When their elements are mapped,
there are clear commonalities, reducing the complexity for
would be reviewers:
• a systematic review question (covering, where relevant,
PICOS/T)
• background justifying the case for a systematic review
• a review team (expertise and experience in subject area
and in conducting systematic reviews)
• a systematic review protocol (potentially registered/
published)
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• a search strategy (including search terms, inclusion and
exclusion criteria, study design, databases and grey
literature)
• duplicate, independent critical appraisal
• duplicate, independent data extraction
• synthesis of data (method of combining results,
subgroup analysis)
• reporting template and/or checklists (key findings,
validity, potential biases, future agenda for
research).
Table 3 A selection of widely recognised resources (guidance, checklists and tools) designed to promote quality in systematic reviews
Resources: guidance, checklists and tools Last
updated
Purpose Critique
AMSTAR a measurement tool to assess
systematic reviews
2007 Eleven item online and printer friendly
tool with comprehensive guidance to
calculate quality and risk of bias
Currently under review aiming to improve
on original validated form. Addition tool
AMSTAR-NRS (non-randomised
studies) under development
CASP Critical Appraisal Skills Programme 2006 Wide range of educational resources, tools
and checklists to aid critical appraisal of
papers identified for review
Public Health Resource Unit provides an
accessible set of tools and training
options to help all stakeholders ‘make
sense of the evidence’. Widely used and
recommended by academics and
educators
CEBM Centre for Evidence Based
Medicine
2016 Primarily aimed at medics and medical
students, provides education and
training, recommended reading as well
as checklists and tools and CATMaker
(critically appraised topics)
Evidence Based Medicine and Baking
offers a novel demonstration of the
hierarchy of evidence as a sponge cake
but also available as a colourful
powerpoint. Accessibility extends to
multilingual translations of critical
appraisal tools and worksheets
Cochrane Handbook for Systematic
Reviews of Interventions
2011 Comprehensive guidance and support from
expert community of special interest
groups. Involves a commitment to
maintaining and updating
Earned its reputation to be considered the
gold standard guidance for systematic
reviews of interventions. Excellent peer
review process. Extensive online training
for authors including use of RevMan
CRD Prospero Centre for Review and
Dissemination Guidance for Undertaking
Reviews in Health Care including
PROSPERO (International Prospective
Register of Systematic Reviews)
2009 Open access register of reviews aiming to
reduce duplication of effort amongst the
international healthcare community
Rapid review prior to acceptance on to the
register. Provides an open access audit
trail of review progress. Although the
protocols are detailed, they are also
readily accessible and ‘write-able’
EQUATOR Enhancing the QUAlity and
Transparency Of health Research
2007 Range of widely recognised tools to
‘promote, teach and practice accurate,
complete and ethical publication of
health research’
Includes COREQ Consolidated criteria for
reporting qualitative research 32-item
checklist for interviews and focus groups
and STROBE 22-item checklist for
Strengthening the Reporting of
Observational Studies in Epidemiology.
Also available in Spanish
JBI Joanna Briggs Institute Systematic
review resource package
2014 Aims to guide consistency in conducting
and reporting healthcare reviews
Would be reviewers must complete a full
set of training modules including use of
templating software Sumari and CReMS.
Excellent support for protocol
development but data extraction software
can feel less than transparent to novice
reviewers
PRISMA Statement Preferred Reporting
Items for Systematic Reviews and Meta-
Analyses
2009 Reporting checklist and flow diagram for
transparency of process available in 8
languages
Detailed and widely used checklist of 27
items and flow diagram. Useful
explanatory paper published
PRISMA-P Preferred Reporting Items for
Systematic Reviews and Meta-Analyses
Protocols
2015 Protocol checklist for completeness and
transparency of process
Comprehensive with 17 items based on
CDSR, PROSPERO, AHRQ. Useful
explanatory paper published. Also in
2015, PRISMA-IPD (individual patient
data) and PRISMA-NMA (network meta-
analyses)
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Limitations
This rapid review was limited to the database of one
journal over a period of 6 years. Although the review was
conducted systematically, it is not presented as a system-
atic review.
Conclusion
This rapid review article posed the question, ‘how sys-
tematic is systematic?’, before identifying uses and types of
reviews, and key factors which limit claims to be system-
atic. The burgeoning evidence industry offers the tools and
guidelines—some of which are described in Table 3-re-
quired to conduct systematic reviews, and other types of
review, systematically. However, as a research community
we have yet to fully engage and so avoid the common
pitfalls. Therefore the question remains, not just of IJCP
published reviews but potentially all published reviews,
‘how systematic is systematic?’
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